On Monday, BMO Capital Markets adjusted its stance on Novo Nordisk (NYSE:NVO) shares following the release of Phase 3 clinical trial results for the company's diabetes treatment, CagriSema. The price ...

The change in price target comes as Novo Nordisk’s latest data from the REDEFINE-1 study did not live up to investor expectations, raising concerns about the company’s performance and future prospects ...

Novo Nordisk just released phase 3 results for CagriSema, and many analysts and investors were disappointed with the data. While the once-weekly injectable led to 22.7% weight loss over 68 weeks ...

The change in price target comes as Novo Nordisk's latest data from the REDEFINE-1 study did not live up to investor expectations, raising concerns about the company's performance and future ...

BMO Capital lowered the firm’s price target on Novo Nordisk (NVO) to $105 from $156 and keeps an Outperform rating on the shares after CagriSema’s Phase 3 data readout failed to meet investor ...

The dip came after data from Novo Nordisk showed patients using its experimental obesity shot CagriSema lost less weight than predicted in a study. Novo shares tanked as much as 29% after the news, ...

Novo Nordisk (NVO) plunged to a 52-week low on Friday after the Danish drugmaker released Phase 3 results for its next-gen weight loss therapy, CagriSema, as data gave a pause for its investors ...

Novo Nordisk (NVO) shares crashed on Friday, while its rival Eli Lilly (NYSE:LLY) surged after the Danish drugmaker posted late-stage trial data for its next-gen weight loss therapy, CagriSema.

Promising combination drug amycretin will also have subcutaneous data and could move to pivotal studies.” “We’re maintaining our $86 fair value estimate for Novo Nordisk, and we continue to ...

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... after posting disappointing late-stage trial data. "We plan to optimise dose titration to further explore ...